Form 4: Vanda Pharmaceuticals CEO Buys $47,650 in Company Stock

Vanda Pharmaceuticals' CEO, Mihael Hristos Polymeropoulos, increased his holdings by purchasing 10,000 shares of VNDA common stock.

Summary

• On February 26, 2025, Mihael Hristos Polymeropoulos, the President and CEO of Vanda Pharmaceuticals, purchased 10,000 shares of VNDA common stock.
• The purchases were made in two transactions, each for 5,000 shares.
• The first 5,000 shares were bought at a price of $4.75 per share, and the second 5,000 shares were bought at $4.78 per share.
• Following these transactions, Polymeropoulos directly owns 2,341,730 shares of Vanda Pharmaceuticals.
• The filing indicates that Polymeropoulos is also the Chairman of the Board.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO buying shares is generally a good sign, but it's a relatively small transaction compared to his existing holdings.

Positives

• The CEO's purchase of company stock could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider buying is often monitored by investors as an indicator of management's confidence in the company's prospects. However, it's just one data point and should be considered alongside other factors.

Stakeholder Impact

• The stock purchase could have a slightly positive impact on shareholder sentiment.

Key Dates